Reviewing the potential of psychedelics for the treatment of PTSD

The extracted text does not present a formal Methods section describing search strategy, inclusion criteria, or review methodology. From the content it appears to be a narrative, topical review rather than a systematic review or meta-analysis: the authors summarise preclinical and clinical findings and synthesise therapeutic rationales, administration practices, and safety data for four compound classes. Krediet and colleagues structure the review by drug class. For each they outline historical background, proposed neurobiological and psychological mechanisms, the clinical setting typically used in research or practice, routes and dosing reported in the literature, available clinical trial evidence (including small trials, RCTs, pooled analyses, and observational reports where applicable), and commonly reported adverse effects. Where trial data are cited, sample sizes and key outcome summaries are reported in the text; however, the extraction does not specify systematic study selection, databases searched, or quality assessment methods.

MDMA: Early clinical work resumed around 2000 after decades of prohibition. Small open-label and randomized studies have been conducted, and a pooled analysis across six controlled trials totalling 105 patients is reported. After two MDMA-assisted psychotherapy sessions, 54.2% of treated patients no longer met PTSD diagnostic criteria compared with 22.6% in control conditions. One early RCT (12 patients receiving 125 mg MDMA versus 8 placebo) found 83% of MDMA patients fell below CAPS-IV PTSD cutoff versus 25% of controls; effects persisted in long-term follow-up. Typical administration in trials is oral MDMA (75–125 mg with a possible half-dose booster), delivered in 2–3 sessions spaced about a month apart, embedded in an extensive psychotherapeutic protocol with preparatory and integration sessions, two therapists, and music-assisted, nondirective sessions lasting 5–8 hours. Reported acute side effects include anxiety, jaw tightness, headache and fatigue; MDMA causes dose-dependent increases in heart rate and blood pressure, and authors note concerns raised elsewhere about neurotoxicity and abuse liability although these were not observed in medically supervised trials. The FDA granted MDMA-assisted psychotherapy breakthrough designation and multicentre Phase 3 trials are underway. Ketamine: Ketamine shows rapid but typically transient antidepressant and anti-PTSD effects. The only RCT in PTSD reported in the extraction compared a single i.v. 0.5 mg/kg ketamine infusion with low-dose midazolam (0.045 mg/kg) in 41 chronic PTSD patients: ketamine produced a significant and rapid reduction in PTSD symptoms that remained significant up to 7 days. Repeated-infusion data are limited but promising: one small study of 6 i.v. ketamine infusions (0.5 mg/kg) over 12 days in 15 military veterans with comorbid PTSD and treatment-resistant depression reported a PTSD remission rate of 80% (PCL-5 <33) with a median time to relapse of 41 days. A trial combining a single ketamine infusion with a mindfulness-based cognitive protocol (trauma activation, mindfulness cycles during infusion) showed longer durability of benefit—34 days in the ketamine group versus 16 days in the control group—compared with single-dose ketamine without psychotherapy. Typical psychiatric dosing is 0.5 mg/kg i.v. over 40 minutes, though intranasal, intramuscular and oral routes are also used. Adverse effects commonly reported include dissociation, perceptual changes, drowsiness, dizziness, nausea and transient increases in heart rate and blood pressure; some such effects may be viewed as therapeutically useful in a substance-assisted psychotherapy model. Classical psychedelics (psilocybin, LSD, DMT/ayahuasca): These 5-HT2A agonists have a long history of clinical use in the mid-20th century but no formal modern RCTs for PTSD have been reported in the extracted text. Preclinical and clinical findings from other indications are cited to support potential relevance to PTSD: facilitation of fear extinction in animal studies, promotion of neural plasticity (neurogenesis, spinogenesis, synaptogenesis), reductions in amygdala reactivity, increased insight, divergent thinking, emotional empathy, and the capacity for ‘‘mystical-type’’ or emotional breakthrough experiences that have mediated therapeutic gains in other disorders. Typical administration in modern protocols mirrors MDMA-assisted models—doses such as 10–25 mg psilocybin or 50–200 µg LSD given orally in 1–3 sessions with preparatory and integration therapy in a comfortable setting with two guides and music. Historical psycholytic approaches and more recent evidence from other indications motivate clinical investigation, and some researchers are planning or collecting data on ayahuasca for PTSD, but the authors note unpredictability and potential for heightened arousal as important considerations. Cannabinoids: The review distinguishes whole-plant cannabis and synthetic cannabinoids (for example, nabilone, dronabinol) acting on the endocannabinoid system. Cannabinoids have been studied mainly for symptomatic relief of insomnia and trauma-related nightmares and for sleep and hyperarousal symptoms. One small open-label study prescribed 5 mg sublingual THC twice daily in 10 outpatients and reported improvements in global symptoms, sleep quality and nightmares, though interpretation is limited by small size and lack of controls. A placebo-controlled cross-over trial of nabilone in 10 military PTSD patients found significant improvement in recurring/distressing dream scores and other measures after 7 weeks of nabilone versus placebo. Larger observational reports (n=47 chart review; n=104 retrospective inmate study) also suggested benefit for nightmares and sleep. Routes of administration and dosing vary widely; acute effects last roughly 2–8 hours depending on route. Side effects include dry mouth, dizziness, fatigue, occasional nausea and, at higher doses, anxiety; cannabinoids may increase risk of psychosis in susceptible individuals and carry potential for cannabis use disorder with frequent recreational use. Comparative and practical observations: MDMA-assisted psychotherapy is presented as the most advanced approach in PTSD-specific trials with sustained reductions in symptoms after a small number of supervised sessions. Ketamine offers rapid but generally short-lived benefit as a standalone intervention, with potential for augmentation if repeated or combined with psychotherapy. Classical psychedelics show plausible mechanisms and encouraging data from other indications but lack contemporary PTSD RCTs. Cannabinoids have modest, mostly symptomatic evidence and remain the only class commonly prescribed as take-home, daily medication for PTSD symptoms.

Krediet and colleagues interpret the literature as indicating that psychedelic compounds offer distinct but complementary opportunities to improve PTSD care. They contend that these substances may be used either to rapidly reduce symptoms (as exemplified by ketamine) or to catalyse and deepen psychotherapeutic processing (as with MDMA and classical psychedelics), and that cannabinoids may be valuable for symptomatic control of sleep and nightmares. MDMA is highlighted for its apparent capacity to reduce fear and shame while increasing interpersonal trust and openness—qualities that may uniquely support trauma-focused work and account for sustained symptom reductions observed in clinical trials. Ketamine is described as producing large but typically transient symptom relief, and the authors note that embedding ketamine in a psychotherapeutic framework or repeating infusions may prolong benefits. The authors situate these findings within earlier research on psychotherapy and memory processes, noting that mechanisms proposed for the psychedelics include reduced amygdala reactivity, enhanced synaptic plasticity, facilitation of fear extinction and disruption of memory reconsolidation, increases in empathy and insight, and strengthened therapeutic alliance. They also emphasise that different drugs have different safety and experiential profiles—classical psychedelics may produce stronger ego-dissolution and variable psychological effects that could be destabilising for some PTSD patients, whereas MDMA tends to produce a milder, more predictable state that might serve as a preparatory step before other psychedelics. Key limitations acknowledged in the extracted text include the paucity of high-quality PTSD trials for most compounds (no modern RCTs for classical psychedelics in PTSD; small sample sizes in several studies), the short duration of benefit after single ketamine infusions, and uncertainties about optimal dosing, timing relative to psychotherapy, patient selection and contraindications. The authors also note concerns about long-term risks—particularly for cannabinoids and for potential abuse liability—and about generalisability given that many trials exclude individuals with cardiovascular disease, psychosis history or bipolar disorder. For future research, the authors outline multiple priorities: conducting more rigorous safety and efficacy trials (including larger RCTs and trials embedding drugs within psychotherapeutic protocols), clarifying contraindications and identifying which patients are most likely to benefit, elaborating neurobiological mechanisms via pre- and post‑treatment assessments, testing different psychotherapeutic modalities (nondirective versus directive approaches) and timing of interventions, and evaluating cost-effectiveness because substance-assisted psychotherapy is resource intensive. They also argue for development of specialised therapist training, supervision, and clinical infrastructure to ensure safe delivery if these treatments are approved. The authors caution that these therapies may not become first-line options quickly because of required expertise and settings, but suggest they could nevertheless offer important new options for patients with chronic or treatment‑resistant PTSD.